Today, Alzheimer’s affects more than five million people in America. According to the Alzheimer’s Association, that number will triple in the next 40 years, and by 2050, caring for patients with Alzheimer’s and other forms of dementia is expected to cost the United States more than $1 trillion annually. Given the tremendous looming human and financial costs, more and more attention and resources are being devoted to finding new ways to treat those with Alzheimer’s disease and, ultimately, find a cure.
Most Recent Posts
The U.S. pharmaceutical supply chain is the most secure in the world in part because of strong industry and government collaboration. One benefit is that American patients can have confidence that the prescription medications they purchase from a reputable pharmacy are true to the label.
Personalized Medicine was an emerging field of medicine in 2005 when we first held what was to become an annual event, our personalized medicine conference. The importance of personalized medicine was given a boost by the then U.S. Secretary of Health and Human Services, Michael Leavitt, who said in January 2005, “I believe we are moving into a remarkable and powerful new era in medicine and particularly in prescription drugs.
Less than 15 years ago, submitting an application to the Food and Drug Administration (FDA) for the approval of a new medicine generally involved loading docks, moving trucks, and enough paper to obliterate a small tree farm. Today, those data once supplied on hundreds of thousands of paper pages are now a structured collection of electronic files submitted to the FDA through a secure portal.
Yesterday, the Senate Finance Committee held its first hearing on the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive free trade agreement that the U.S. and European Union have begun negotiating.
Yesterday, I had the opportunity to speak at a conference of regulatory and compliance professionals – those who are dedicated to ensuring that regulation works.
Millions of prescriptions are filled every year in the United States and the patients who depend on these medications must have confidence in their safety and authenticity.
A survey commissioned earlier this year by PhRMA shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities.
Until this morning, on the rare occasions when I thought of Omaha, Nebraska, I would conjure up images of Warren Buffett, thick juicy steaks, a clean quiet Midwestern city and friendly, laid-back folks, not necessarily in that order.
I learned today that I was not inaccurate, all of the above is true, but my picture was far from complete.
Alzheimer’s has proven to be a stubborn, puzzling and perhaps even symbolic disease. In recent years, it has emerged as one of our greatest tests of biopharmaceutical science because of the disease’s vast and growing impact on the health of our aging population and the viability of our health care system.
Today, PhRMA will be hosting a stakeholder action group meeting with the National Council for Prescription Drug Programs (NCPDP) called “Maximizing Prescription Quality Through ePrescribing.” NCPDP is a non-for-profit, American National Standards Institute (ANSI) certified standards development organization.
How can we continue to advance cancer research and improve patient outcomes in an era of cost containment? The issue was recently highlighted in a New York Magazine article that only provided part of the story on cancer progress and cost containment. Last week I had the opportunity to tackle this question as part of a roundtable that convened leaders from across the cancer community.